دورية أكاديمية

Mesoporous Silica Particles Functionalized with Newly Extracted Fish Oil (Omeg@Silica) Reducing IL-8 Counteract Cell Migration in NSCLC Cell Lines

التفاصيل البيبلوغرافية
العنوان: Mesoporous Silica Particles Functionalized with Newly Extracted Fish Oil (Omeg@Silica) Reducing IL-8 Counteract Cell Migration in NSCLC Cell Lines
المؤلفون: Claudia D’Anna, Caterina Di Sano, Serena Di Vincenzo, Simona Taverna, Giuseppe Cammarata, Antonino Scurria, Mario Pagliaro, Rosaria Ciriminna, Elisabetta Pace
المصدر: Pharmaceutics, Vol 14, Iss 10, p 2079 (2022)
بيانات النشر: MDPI AG, 2022.
سنة النشر: 2022
المجموعة: LCC:Pharmacy and materia medica
مصطلحات موضوعية: omega-3, lung cancer cells, cancer cell migration, inflammation, fish oil, PUFA, Pharmacy and materia medica, RS1-441
الوصف: Lung cancer is one of the leading forms of cancer in developed countries. Interleukin-8 (IL-8), a pro-inflammatory cytokine, exerts relevant effects in cancer growth and progression, including angiogenesis and metastasis in lung cancer. Mesoporous silica particles, functionalized with newly extracted fish oil (Omeg@Silica), are more effective than the fish oil alone in anti-proliferative and pro-apoptotic effects in non-small cell lung cancer (NSCLC) cell lines. The mechanisms that explain this efficacy are not yet understood. The aim of the present study is therefore to decipher the anti-cancer effects of a formulation of Omeg@Silica in aqueous ethanol (FOS) in adenocarcinoma (A549) and muco-epidermoid (NCI-H292) lung cancer cells, evaluating cell migration, as well as IL-8, NF-κB, and miRNA-21 expression. Results show that in both cell lines, FOS was more efficient than oil alone, in decreasing cell migration and IL-8 gene expression. FOS reduced IL-8 protein release in both cell lines, but this effect was only stronger than the oil alone in A549. In A549, FOS was able to reduce miRNA-21 and transcription factor NF-κB nuclear expression. Taken together, these data support the potential use of the Omeg@Silica as an add-on therapy for NSCLC. Dedicated studies which prove clinical efficacy are needed.
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 1999-4923
Relation: https://www.mdpi.com/1999-4923/14/10/2079; https://doaj.org/toc/1999-4923
DOI: 10.3390/pharmaceutics14102079
URL الوصول: https://doaj.org/article/c77a55f633994a41ab9792aee4c7ea37
رقم الأكسشن: edsdoj.77a55f633994a41ab9792aee4c7ea37
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:19994923
DOI:10.3390/pharmaceutics14102079